What experts said about PT-141 in Q2 2026

Between March and June 2026, the expert conversation around PT-141 (bremelanotide) shifted on two fronts: new peer-reviewed work pushed the question of whether this melanocortin agonist should be studied more seriously in men, and a systematic review from Harvard-affiliated researchers confirmed its place in the female sexual-dysfunction treatment landscape. Meanwhile, Palatin Technologies reported positive topline data from a Phase 2 study combining bremelanotide with a GLP-1 agonist for obesity, signalling that the molecule's future may extend well beyond sexual health. This digest collects the on-record expert commentary, notes credentials and conflicts of interest, and lets readers compare the positions side by side.

The case for studying bremelanotide in men

James G. Pfaus, a neuroscientist at Charles University in Prague with decades of published work on the neurobiology of sexual behaviour, and Richard Balon, a psychiatrist at Wayne State University, co-authored a commentary in the Journal of Clinical Psychopharmacology (May/June 2026) titled "Should Bremelanotide Be Considered for the Treatment of Sexual Arousal and Desire Disorders in Men?" The paper argues that the existing preclinical and early clinical evidence warrants formal investigation of bremelanotide for male sexual dysfunction, a use that currently sits entirely outside the FDA-approved indication^[1]. (COI: Pfaus has consulted for Palatin Technologies, the originator of bremelanotide.)

The Pfaus and Balon commentary builds on a thread that the Goldstein father-son team at San Diego Sexual Medicine have been pulling for several years. In a presentation at the Sexual Medicine Society of North America's 2024 meeting, published in the Journal of Sexual Medicine, Scott W. Goldstein and Irwin Goldstein reported on 22 men with various sexual dysfunctions who were prescribed off-label subcutaneous bremelanotide over a 46-month period (Goldstein & Goldstein, J Sex Med 2024). Among those who completed questionnaires, 76% reported greater satisfaction with lovemaking, 83% found vaginal insertion easier, and 70% showed clinically meaningful improvement on the Patient Global Impression of Improvement scale^[1]. The study is observational, uncontrolled, and small (n=22), but the refill rate -- 73% of men refilled, compared with 47-52% of women in the same clinic -- suggests a population that found the drug useful enough to continue paying for it.

Bremelanotide safely and effectively improved multiple sexual dysfunctions for some men.

Bremelanotide confirmed in the female treatment toolkit

On the approved-indication side, a systematic review and meta-analysis by Toledo and colleagues at Beth Israel Deaconess Medical Center and Harvard Medical School, published in the Journal of Minimally Invasive Gynecology (January 2026), screened 8,994 abstracts, reviewed 278 full-text articles, and included 36 studies in their analysis of treatments for female sexual desire, arousal, and orgasmic dysfunctions. Their finding: bremelanotide improved total FSFI (Female Sexual Function Index) scores and its desire and arousal subscales, and reduced sexual distress^[2]. The review distinguished bremelanotide from flibanserin, which primarily addressed desire alone, positioning bremelanotide as the broader-acting pharmacological option for women with both desire and arousal complaints.

This matters because the original RECONNECT pivotal trials (Kingsberg et al., 2019) enrolled only premenopausal women with HSDD, and the effect sizes, while statistically significant, were modest. The Toledo meta-analysis pools data across multiple studies and confirms the direction of effect, though it does not resolve the question of clinical meaningfulness for individual patients. The Vyleesi label, now held by Cosette Pharmaceuticals after their January 2024 acquisition from Palatin, remains unchanged: 1.75 mg subcutaneous injection, as needed, no more than 8 doses per month^[3].

Beyond sexual health: the obesity pivot

The most unexpected development this quarter came from Palatin Technologies' pipeline page: positive topline data from a Phase 2 proof-of-concept study combining a melanocortin-4 receptor (MC4R) agonist with a GLP-1 agonist in obese patients, reported in Q1 2025^[4]. Palatin does not name bremelanotide specifically in this context -- the company's MC4R pipeline now targets hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome -- but the pharmacological logic is bremelanotide's: MC4R activation in the hypothalamus modulates appetite and energy balance through the same receptor family that drives its sexual-desire effects.

Separately, Palatin had previously projected topline data from a Phase 3 trial of bremelanotide co-formulated with a PDE5 inhibitor for erectile dysfunction in PDE5i non-responders by the first half of 2026. As of this writing (June 2026), no topline readout has been publicly disclosed, and the ED programme is no longer prominently featured on Palatin's pipeline page^[4]. Whether this reflects a strategic deprioritisation, a timeline slip, or simply a gap in public disclosure is not clear from available information.

What the regulatory picture looks like

Bremelanotide occupies a different regulatory category from the grey-market peptides (like BPC-157, TB-500, and ipamorelin) headed to the FDA's Pharmacy Compounding Advisory Committee on July 23-24, 2026. As an FDA-approved drug (NDA 210557, June 2019), Vyleesi is already lawfully available by prescription in the United States. It is not on the PCAC review agenda.

Outside the US, the picture is sharply different. The EMA has no marketing authorisation for bremelanotide. The MHRA in the UK has no marketing authorisation either. Lawful access in the EU, EEA, and UK runs only through unlicensed-medicine or named-patient routes. Off-label use in men, in any jurisdiction, falls outside the controlled-trial evidence base and the FDA-approved indication. For the jurisdiction-specific picture, see the PT-141 page on this site.

What to make of the quarter

The Q2 2026 PT-141 conversation is structurally different from the debates around unapproved peptides. Bremelanotide has a completed Phase 3 programme, an FDA approval, a commercial product, and a growing (if still small) off-label evidence base in men. The Pfaus and Balon commentary is not arguing from animal data and forum anecdotes; it is pointing to a molecule with a characterised safety profile and asking why formal male trials have not happened. The Goldstein clinic data, while preliminary, shows real patients returning for refills in a fee-for-service context.

The gaps remain real. No randomised controlled trial of bremelanotide in men has been completed. The Palatin ED co-formulation programme's status is unclear. Postmenopausal women are not covered by the approval or the pivotal data. Whether the obesity-adjacent MC4R work will loop back to bremelanotide itself, or stay with newer Palatin compounds, is unknown. And the 40% nausea rate from the RECONNECT trials remains the dominant tolerability signal, one that no dose adjustment or pre-treatment strategy has convincingly solved^[3].

For readers considering bremelanotide, the conversation belongs with a clinician who knows your medical history, not with a peptide vendor or a podcast. The FDA-approved product (Vyleesi) exists for a specific, narrow indication. Everything else is off-label, and the evidence for those uses is preliminary at best. For background on the compound, its mechanism, and its regulatory status in your jurisdiction, see the PT-141 page on this site.